Syndivia Unveils New Clinical Asset Featuring Proprietary ADC Linker Technology

Strasbourg, France, Apr. 22, 2024 – Syndivia, a leading biotechnology ADC (antibody-drug conjugates) company, is proud to announce the unveiling of a clinical asset showcasing its proprietary high-stability ADC linker technology (APN).

Developed in collaboration with Inatherys, this candidate marks a significant milestone in the field of oncology therapeutics. The new clinical asset, INA03, represents a potent transferrin-competitive antibody-drug conjugate with improved stability in plasma designed to target CD71, with the aim of revolutionizing acute leukemia treatment. This innovative ADC has been years in the making, with Syndivia and Inatherys jointly overcoming numerous challenges to bring this promising candidate into the clinic (ClinicalTrials.gov identifier: NCT03957915).

Learn more: https://aacrjournals.org/mct/article-abstract/doi/10.1158/1535-7163.MCT-23-0548/743156/INA03-a-potent-transferrin-competitive-antibody

Renowned Nobel Laureate Jean-Marie Lehn Appointed Chairman of Syndivia's Scientific Advisory Board

Strasbourg, France, Nov. 16, 2023 – Syndivia, a leading biotechnology company at the forefront of innovative DAR1 ADCs (antibody-drug conjugates with a drug-to-antibody ratio of 1), is excited to announce the appointment of Nobel Prize-winning chemist, Professor Jean-Marie Lehn, as the Chairman of the company's Scientific Advisory Board (SAB).

Professor Lehn, who was awarded the Nobel Prize in Chemistry in 1987 for his groundbreaking work on supramolecular chemistry, brings a wealth of expertise and experience to Syndivia. His leadership as Chairman of the SAB will play a pivotal role in guiding and advancing Syndivia's cutting-edge research and development initiatives in the field of ADCs.

 

Syndivia's CEO, Sasha Koniev, expressed excitement about the appointment, stating, "We are honored to welcome Professor Jean-Marie Lehn to Syndivia. His outstanding contributions to the field of supramolecular chemistry, coupled with his visionary approach to scientific innovation, align seamlessly with our commitment to pushing the boundaries of ADCs. We are confident that Professor Lehn's guidance will be instrumental in shaping the future of Syndivia."

 

As Chairman of the SAB, Professor Lehn will work closely with Syndivia's research and development teams, providing strategic insights and fostering collaboration with other scientific leaders. His role will contribute to advancing Syndivia's mission of developing breakthrough therapies for unmet medical needs.

 

Professor Jean-Marie Lehn commented on his new role, saying, "I am thrilled to join Syndivia and contribute to their pioneering efforts in drug discovery. The intersection of chemistry and biotechnology holds great promise, and I look forward to working with the talented team at Syndivia to drive innovation and make a lasting impact on healthcare."

About Syndivia: Syndivia is a biotechnology company dedicated to revolutionizing the field of ADC therapeutics through cutting-edge research and development. The company focuses on harnessing the distinctive properties of its proprietary ADC platform, which provides improved efficacy.

The Press release is available on PRNewswire

Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies

Luxembourg, January 13th, 2022 – TVM Life Science Innovation II SCSp announced the Fund’s investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA.

Auricula Biosciences plans to develop a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. This conjugate targets macropinocytosis, a unique feature of cancer cells harboring K-Ras mutations.

Full press release is available on TVM Capital Life Science website.

Syndivia Receives €2m Deeptech Financing From Bpifrance to Advance Its Lead Immunoconjugate for Solid Cancers

STRASBOURG, France, March 10, 2020 – Syndivia, a research-driven biotechnology company focused on the development of new therapeutic modalities for cancers, announced today that it will benefit from €2 m deep tech financing from Bpifrance. Proceeds will be used to further fund the advancement of one company's drug candidate towards the clinic.

The Deeptech plan was initiated by the French government and has been deployed by Bpifrance since 2019 to support deep tech startups resulting from research based on breakthrough innovations. The main objective is to allow these companies to grow, and to stimulate innovation by strengthening the links between academia and the entrepreneurial world.

Sasha Koniev, CEO of Syndivia, said, "We are very grateful to Bpifrance for this generous support. This financing will largely accelerate the development of our lead immunoconjugate for various cancer indications, which to date have a very limited number of effective treatment options."

Commenting on this news, Alban Stamm, in charge of innovation at Bpifrance, said, "Syndivia, which initially emerged from the research of academic laboratories supported by SATT Conectus and reinforced with iLab 2014 (emergence) and 2015 (development) grants, succeeded in bringing together all the ingredients to meet technological challenges. At Bpifrance, we appreciate Syndivia's progress to date and especially value the team: initially composed of young researchers with strong entrepreneurial capacity, it surrounded itself with an experienced board bringing together all the key success factors of a biotech startup."

About Bpifrance

Bpifrance is the French national investment bank. It finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services such as training and consultancy to help entrepreneurs meet their challenges.

www.bpifrance.com

About Syndivia

Syndivia is a biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a specific targeting of the tumor microenvironment and anatomical hallmarks of solid tumors. Syndivia's mission is to develop new therapies for patients with the most difficult-to-treat cancer indications.

https://www.syndivia.com.

Media Contact

Syndivia
Sasha Koniev, CEO
Phone: 00 33 3 67 10 42 20
Email: enquiry@syndivia.com

https://www.prnewswire.com/news-releases/syndivia-receives-2m-deeptech-financing-from-bpifrance-to-advance-its-lead-immunoconjugate-for-solid-cancers-301020574.html

Syndivia In-Licenses DARx Technology for 1-to-1 Linkage of Antibodies and Payloads for Preparation of DAR1 ADC

Syndivia has acquired an exclusive license from SATT Conectus for DARx technology, which enables the generation of 1-to-1 conjugates (DAR1) using readily available protein substrates, such as therapeutic antibodies. The antibody-drug and antibody-oligonucleotide conjugates with a degree of conjugation of 1 (DAR1), produced through DARx, have demonstrated improved therapeutic indices owing to enhanced pharmacokinetics and pharmacodynamics (PK/PD) parameters.

ADC DAR1 (antibody-drug conjugation with drug-to-antibody ratio of one)

For more information, please refer to: https://www.prnewswire.com/news-releases/syndivia-in-licenses-darx-technology-for-1-to-1-linkage-of-antibodies-and-payloads-for-preparation-of-new-classes-of-biologics-300993733.html

Syndivia In-Licenses Novel Antibody Against Tumor-Specific Form of CD146 From SATT Sud-Est

  • Syndivia receives the exclusive sublicense specifically for immunoconjugates of the monoclonal antibody against the tumor-specific form of CD146 (CD146-ts mAb).

  • CD146-ts is a promising target and represents a first-in-class opportunity for the treatment of a number of solid cancers, including melanoma and pancreatic cancer.

 

Strasbourg and Marseille, France, Jan. 16, 2020 – Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks, announced today that it has been granted an exclusive, worldwide sublicense by SATT Sud-Est to the immunoconjugates of the anti‑CD146-ts antibody (excluding diagnosis), which binds a tumor-specific form of CD146 found on a number of solid cancers. CD146-ts has a central role in the mechanism of tumorigenesis and has the potential to address a current unmet need in cancer therapy. The development of novel biologic entities (NBE) targeting CD146-ts will be undertaken by Syndivia in Strasbourg, France.

Commenting on this deal, Dr. Sasha KONIEV, Syndivia’s CEO, said “We are excited to have been granted the sole and exclusive sublicense to commercialize the immunoconjugates against this tumor-specific form of CD146. We are enthusiastic about the addition of this candidate to the Syndivia discovery pipeline and will leverage our expertise in bioconjugation to rapidly progress its preclinical development.”

“We are extremely pleased that Syndivia shares our excitement for the CD146-ts mAb project and look forward to the next stages of development with great enthusiasm,” said Dr. Marcel BLOT-CHABAUD, inventor of anti-CD146-ts antibody and leader of the “New Molecular Targets” team at C2VN, Aix-Marseille Université, INSERM, INRA, Marseille, France.

"We could not be any happier when transferring such a first-in-class opportunity for the treatment of solid cancers, with the sole aim of transforming the invention into an innovation – especially when the nature of the identified target makes it possible to identify a relevant lead for the most aggressive and refractory forms to current treatments,” concluded Laurent BALY, President of SATT Sud-Est.

Syndivia will undertake further development and commercialization of anti-CD146-ts immunoconjugates in exchange for undisclosed upfront, milestone and royalty payments to SATT Sud-Est.

About CD146-ts

CD146-ts represents a novel target in a number of the deadliest therapeutic indications in oncology, including melanoma and pancreatic cancer. Due to its important role in tumorigenesis and confirmed tumor-specific expression in patient-derived samples, anti-CD146-ts immunoconjugates have the potential to become new therapeutic modalities in a number of solid cancer indications.

About C2VN (Aix-Marseille Université, INSERM, INRA)

The Cardiovascular and Nutrition Research Centre (C2VN, UMR_S 1263, UMR 1260, Aix-Marseille Université, INSERM, INRA) shows expertise in all pathways and targets involved in pathologies with a vascular component, including cancer pathology, with the aim of identifying innovative biomarkers and biotherapies. To support its studies, the C2VN has developed many platforms, tools and experimental models related to the targeted pathologies. For more information, visit https://c2vn.univ-amu.fr.

About SATT Sud-Est ­| From dream to reality, from lab to market

A researcher and his/her team make an extraordinary discovery. But how can an idea be transformed into a solution, and how can an invention be turned into an innovation? This is the start of a race against time to find the partner company capable of upholding that ambition. Fortunately, SATT Sud-Est is there to help in this undertaking and make this great story come true. Transforming an invention into an innovation is a wonderful experience. And we’re fortunate, it is our job. Find out how SATT Sud-Est accelerates technology transfer by bringing together research and business players. From the patent to the operating license agreement, SATT Sud-Est stands out in France’s South and Corsica regions as an essential innovation player. Visit www.sattse.com and twitter @SATTse_

About Syndivia

Syndivia is a research-driven biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a unique microenvironment and anatomical hallmarks for these tumors. Syndivia’s mission is to develop new therapies for patients with the most difficult cancer indications. For more information, visit https://www.syndivia.com.

 

Media Contact

Syndivia
Sasha KONIEV – CEO
Phone: +33 (0)3 67 10 42 20
email: enquiry@syndivia.com

https://www.prnewswire.com/news-releases/syndivia-in-licenses-novel-antibody-against-tumor-specific-form-of-cd146-from-satt-sud-est-300988302.html

Syndivia Raises €1M Investment to Advance Its Tumour Microenvironment Drug Delivery Platform

Strasbourg, France,  Dec 10, 2019 – Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on a specific targeting of the tumour microenvironment and anatomical hallmarks, announced a €1M investment from Cap Innov’Est, an inter-regionally based seed fund.

This funding will enable Syndivia to advance its pipeline of proprietary anticancer therapies, including its lead drug candidate (SDV1001), thus completing the preclinical “proof of concept” study of the targeting of the microenvironment of solid tumours.

Sasha Koniev, Syndivia’s CEO, said, “We are very pleased to see Cap Innov’Est joining the company’s founders. This funding will allow us to advance our drug platform for both small-molecule and biologics, which have the unique potential to address a wide range of solid cancer indications by harnessing the specific properties of the tumor microenvironment”.

Jean-François Rax, Investment Director at Cap Innov’Est said, “We are truly enthusiastic to be investing in such a promising company. We are convinced that Syndivia’s breakthrough approach in the hands of its experienced management team will be successful in delivering innovative and efficient treatments for cancer patients.”

About Syndivia

Syndivia is a company that is developing a platform for the targeted therapy of solid cancers by leveraging a unique microenvironment and anatomical hallmarks of these tumours. Syndivia’s mission is to develop new therapies for patients with the most difficult cancer indications. For more information, visit https://www.syndivia.com.

About Cap Innov’Est

Cap Innov’Est is a €45 M French regional seed fund (Grand Est, Bourgogne-Franche-Comté) dedicated to investing in young, innovative start-ups. It was launched in July 2014 and has invested in 25 start-ups to date. Cap Innov’Est is managed by Capital Grand Est along with its partner, Invest PME (Siparex group). Cap Innov’Est is supported by Fonds National d’Amorçage (National Seed Fund), Regions Grand Est and Bourgogne-Franche-Comté, SAFIDI, Caisse d’Epargne d’Alsace and Bourgogne/Franche-Comté, BNP Paribas and CIFC. For more information, visit http://www.capitalgrandest.eu

Media Contact:

Syndivia
Sasha Koniev – CEO
Phone: 00 33 3 67 10 42 20
Email: enquiry@syndivia.com

https://www.prnewswire.com/news-releases/syndivia-raises-1m-investment-to-advance-its-tumour-microenvironment-drug-delivery-platform-300972469.html

Syndivia and BFCL publish review of Antibody–Oligonucleotide Conjugates (AOC) as therapeutic, imaging, and detection agents

Syndivia and Biofunctional Chemistry Laboratory announce publication of a review titled “Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents” in Bioconjugate Chemistry. The review gives a comprehensive overview of the main applications of antibody-oligonucleotide conjugates (AOC) as well as major synthetic approaches used for their preparation. The review emphasized the importance of the development of novel methods for efficient and reliable generation of AOC, in order to advance their new applications.

https://pubs.acs.org/doi/10.1021/acs.bioconjchem.9b00306